{"Clinical Trial ID": "NCT01421472", "Intervention": ["INTERVENTION 1:", "HR+: MM-121+ Paclitaxel", "Sub-group Positive Hormone-Receptor (HR+) randomized to receive:", "2 weeks of injection of MM-121 (20 mg/kg IV infusion weekly over 60 minutes after a load dose of 40 mg/kg), followed by 4 cycles of MM-121 (20 mg/kg IV infusion weekly over 60 minutes) + Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks, followed by 4 cycles of doxorubicin and cyclophosphamide (8 weeks)", "INTERVENTION 2:", "HR+: Paclitaxel only", "Sub-group Positive Hormone-Receptor (HR+) randomized to receive:", "Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks followed by a standard dose of doxorubicin IV and cyclophosphamide IV followed by surgery."], "Eligibility": ["Incorporation criteria:", "\u00b7 Histological confirmation of positive HER2 invasive breast cancer (Group 1) or invasive triple negative breast cancer (Group 2)", "Free from metastatic diseases", "- 18 years", "Women", "No prior treatment for cancer", "Eligibility for treatment with paclitaxel, doxorubicin and cyclophosphamide", "- Exclusion criteria:", "Have a history of severe allergic reactions to paclitaxel or other medicines formulated in Cremaphor\u00ae EL", "Are pregnant or breast-feeding"], "Results": ["Performance measures:", "Number of participants with a complete pathological response (CPR) (CPR rate)", "The complete pathological response was defined as the absence of invasive cancer in the breast and lymph nodes after completion of neoadjuvant systemic treatment and reported under the current system of establishment of AJCC for neoadjuvant clinical studies. The endpoint was to determine the complete pathological response rates (TPR) associated with the weekly treatment of MM-121 plus paclitaxel followed by the combined treatment of doxorubicin plus cyclophosphamide compared to paclitaxel only weekly followed by the combined treatment of doxorubicin plus cyclophosphamide in patients with negative primary breast cancer of receptor 2 (HER2) of the human epidermal growth factor.", "Delay: At the time of surgery, an expected average of 24 to 26 weeks", "Results 1:", "Title of arm/group: HR+: MM-121+ Paclitaxel", "Description of the arm/group: Subgroup Positive Hormone-Receptor (HR+) randomized to receive:", "2 weeks of injection of MM-121 (20 mg/kg IV infusion weekly over 60 minutes after a load dose of 40 mg/kg), followed by 4 cycles of MM-121 (20 mg/kg IV infusion weekly over 60 minutes) + Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks, followed by 4 cycles of doxorubicin and cyclophosphamide (8 weeks)", "Total number of participants analysed: 66", "Type of measurement: Number", "Unit of measure: participants Topics without pCR: 59", "Topics with pCR: 7", "Results 2:", "Title of arm/group: HR+: Paclitaxel only", "Description of the arm/group: Subgroup Positive Hormone-Receptor (HR+) randomized to receive:", "Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks followed by a standard dose of doxorubicin IV and cyclophosphamide IV followed by surgery.", "Total number of participants analysed: 30", "Type of measurement: Number", "Unit of measure: participants Topics without pCR: 29", "Topics with pCR: 1"], "Adverse Events": ["Undesirable Events 1:", "Total: 14/67 (20.90 per cent)", "* 5/67 (7.46%)", "Anemia * 3/67 (4.48%)", "Neutropenia * 0/67 (0.00 %)", "Leucopenia * 0/67 (0.00 %)", "Sinus Tachycardia * 0/67 (0.00 %)", "Diarrhoea * 2/67 (2.99 %)", "Nausea * 1/67 (1.49 per cent)", "Vomiting * 1/67 (1.49 %)", "- Pancreatitis * 1/67 (1.49%)", "Pyrexia * 1/67 (1.49%)", "Bacteria * 0/67 (0.00 %)", "* 0/67 (0.00 %)", "Adverse Events 2:", "Total: 5/33 (15.15 per cent)", "Febrile Neutropenia * 0/33 (0.00 %)", "Anemia * 0/33 (0.00 %)", "Neutropenia * 0/33 (0.00 %)", "Leucopenia * 0/33 (0.00 %)", "Sinus Tachycardia * 0/33 (0.00 %)", "Diarrhoea * 0/33 (0.00 %)", "Nausea * 1/33 (3.03%)", "Vomiting * 1/33 (3.03%)", "Pancreatitis * 0/33 (0.00 %)", "Pyrexia * 1/33 (3.03%)", "Bacteria * 0/33 (0.00 %)", "* 0/33 (0.00 %)"]}